Lyssikatos Joseph P 4

4 · Enliven Therapeutics, Inc. · Filed Feb 17, 2026

AI-generated summary of this filing

Updated Feb 18, 2026

Enliven (ELVN) CSO Joseph Lyssikatos Receives 131,250-Share Award

What Happened

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, was awarded a total of 131,250 shares on February 12, 2026: 18,750 restricted stock units (RSUs) and 112,500 derivative awards. Both grants show an acquisition price of $0.00 (awarded/compensation, not a purchase). These awards are compensatory equity grants, not open‑market purchases or sales.

Key Details

Transaction date: 2026-02-12; Filing date (Form 4): 2026-02-17.
Awards: 18,750 RSUs @ $0.00; 112,500 derivative awards @ $0.00.
Shares owned after transaction: not specified in the provided excerpt of the filing.
Footnotes:
- F1 (RSUs): Each RSU converts to one share when vested. Vesting: 1/4 on March 1, 2027, then 1/16th each June 1, Sept 1, Dec 1 and March 1 thereafter, subject to continued service.
- F3 (derivative award): 1/4 vests on Feb 12, 2027 and then 1/48th vest each month thereafter, subject to continued service (typical option/award vesting schedule).
- F2: Some shares are held in a revocable trust for which Lyssikatos is trustee.
Remark: The filer notes he is no longer deemed a Section 16 executive officer after Feb 12, 2026.
Timeliness: The Form 4 was filed five days after the transaction. Section 16 insiders typically must file within two business days, but the filing indicates a change in officer status effective the transaction date.

Context

RSUs and the listed derivative awards are compensation grants that vest over time; they do not represent immediate sales or market purchases. They become meaningful to the insider only as they vest (and, for options if applicable, are exercised). Such awards are standard executive compensation and should not be read as a direct buy/sell signal.

Form 4Exit

Period: 2026-02-12

CHIEF SCIENTIFIC OFFICER

Transactions

Award
Common Stock
[F1]
2026-02-12+18,750→ 18,750 total
Award
Stock Option (right to buy)
[F3]
2026-02-12+112,500→ 112,500 total
Exercise: $27.16Exp: 2036-02-12→ Common Stock (112,500 underlying)

Holdings

Footnotes (3)

[F1]These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.
[F2]The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
[F3]1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Signature

/s/ Ben Hohl, by power of attorney|2026-02-17

1 file